Seres Therapeutics Analyst Ratings
Oppenheimer Downgrades Seres Therapeutics to Perform From Outperform, Removes $4 Price Target
Analysts Conflicted on These Healthcare Names: Seres Therapeutics (MCRB) and Immunocore Holdings (IMCR)
Buy Rating on Seres Therapeutics Backed by Strong SER-155 Study Progress and Potential in Transplant Health
Seres Therapeutics Analyst Ratings
Buy Rating Affirmed for Seres Therapeutics Amidst Strong Sales Trajectory and Promising Pipeline
Chardan Adjusts Price Target on Seres Therapeutics to $6 From $8, Keeps Buy Rating
Oppenheimer Sticks to Its Buy Rating for Seres Therapeutics (MCRB)
Seres Therapeutics (MCRB) Gets a Buy From TD Cowen
Sell Rating on Seres Therapeutics Amid Underperforming Sales and Financial Challenges
Seres Therapeutics Analyst Ratings
Oppenheimer Trims Seres Therapeutics Price Target to $9 From $10, Maintains Outperform Rating
Analysts Offer Insights on Healthcare Companies: Cellectar Biosciences (CLRB) and Seres Therapeutics (MCRB)
Goldman Sachs Maintains Sell on Seres Therapeutics, Lowers Price Target to $1.25
Seres Therapeutics Analyst Ratings
Oppenheimer Adjusts Seres Therapeutics Price Target to $10 From $12, Maintains Outperform Rating
Oppenheimer Sticks to Its Buy Rating for Seres Therapeutics (MCRB)
Buy Rating for Seres Therapeutics: A Review of Vowst's Success, Restructuring, and SER-155 Prospects
Sell Rating on Seres Therapeutics Amidst Restructuring and Financing Risk Concerns
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Irhythm Technologies (IRTC) and Seres Therapeutics (MCRB)
No Data